Product information and disease description Place of product in therapy Disease description Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Economic burden and healthcare resource utilization

5 evidence topics · 4 sources

Existing treatment burden: SCN8A caregiver survey

“Most patients (77%) were currently taking ≥2 ASMs; 50% had previously tried and stopped ≥4 ASMs.” (opens the source at this quote in a new tab)

SCN2A-related disorders: medical-record study

“Mean number of medications prescribed by records end across phenotypes was 18.1 (range 0-58)” (opens the source at this quote in a new tab)

SCN8A-related disorders: medical-record study

“The mean number of medications prescribed across patients by records end was 17.6 (3-44)” (opens the source at this quote in a new tab)

German burden-of-illness study: registry recruitment status

“Recruiting planned” (opens the source at this quote in a new tab)

German burden-of-illness study: economic outcomes

“Burden-of-illness (direct and indirect costs - inquired over 3 month period, based on Riechmann et al. Epilepsia 2015)” (opens the source at this quote in a new tab)